All
Life After MDS and Accomplishing Your Goals
After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.
Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.
An Expert Shares Her Advice For Managing Side Effects in Cervical Cancer
Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cervical cancer who are experiencing side effects.
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.
Palliative Care May Improve Quality of Life in Esophageal Cancer
End-of-life palliative care consultations may also ease financial strain for patients with esophageal cancer.
Understanding Food Insecurity and Malnutrition During Cancer Treatment
Dr. Anna Arthur discusses how the NOURISH trial is addressing food insecurity and malnutrition in patients undergoing treatment for their blood cancers.
When A Spouse Dies from Cholangiocarcinoma: Praise for Single Parents
Despite the initial shock and challenges, I found strength and support within the community of single parents.
Oral Liporaxel May Be Superior To Intravenous in Advanced Gastric Cancer
Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a second-line therapy.
How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care
Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.
Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC
Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer.
The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer.
Neoadjuvant Keytruda Shows Significant Benefit in dMMR Colon Cancer
Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%.
ctDNA Status May Predict Disease-Free Survival With Celebrex in Colon Cancer
Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA who received Celebrex had significantly better rates versus placebo.
Afinitor Plus Somatuline May Improve Survival in Aggressive GEP-NETs
Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, particularly those with high Ki-67 scores.
CRT and Chemo May Not Improve Survival in Resected Gallbladder Cancer
Among patients with resected gallbladder cancer, the addition of chemoradiation to chemotherapy treatment did not improve relapse-free survival.
Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC
Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.
Aspirin May Reduce Recurrence in PI3K-mutated Colorectal Cancer
Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance of upfront genomic testing.
Cabometyx Shows Promise for Treating Advanced NETs Originating in the GI Tract
A study showed Cabometyx improved time before disease progression in advanced digestive NETs compared with placebo.
Bezuclastinib Plus Sutent May Be Safe and Effective in GIST
Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.
When Cancer Is Not the Only Thing Going On
My journey as a foster parent paralleled my cancer experience, both demanding resilience, support, and a redefinition of normal.
Second Cancer Risk Heightened After Appendiceal Adenocarcinoma Diagnosis
Adults with primary primary appendiceal adenocarcinoma face a higher risk of developing a second primary cancer, including colorectal and prostate cancers.
FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS
The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.
Whitesnake Guitarist John Sykes Died of Cancer, Mike Peters Starting CAR-T
From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.
Opdivo Regimen May Prolong Survival in Chinese Patients With Certain GI Cancers
Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction or esophageal cancer.
Opdivo Plus Chemo Shows 5-Year Efficacy in Gastric, GEJ and Esophageal Cancer
Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.
SHR-1701 Combo Reduces Chemo-Related Myelosuppression in Gastric/GEJ Cancer
SHR-1701 plus chemo suppressed chemo-associated myelosuppression in patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Afinitor Plus Somatuline Prolongs Survival in GEP-NETs
Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.
Matching Patient Needs with Oncologists’ Strengths in Cancer Care
Following a lung cancer diagnosis, I learned that it is important to ask oncologists thoughtful questions to know if they are the best doctor for my needs.
The FDA Accepts a BLA for RP1 Plus Opdivo in Advanced Melanoma
The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.
Driving Awareness, Action and Empowerment During Cervical Cancer Awareness Month
Dr. Ritu Salani discussed Cervical Cancer Awareness Month, highlighting what patients with this disease should be aware of as well as prevention tactics.
